BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9

• Press Releases

  HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

  June 1, 2026

   · 

  9 min read
• Press Releases

  Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

  June 1, 2026

   · 

  5 min read
• Press Releases

  Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

  June 1, 2026

   · 

  7 min read
• Press Releases

  Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

  June 1, 2026

   · 

  20 min read
• Press Releases

  Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

  June 1, 2026

   · 

  13 min read
• Press Releases

  Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

  June 1, 2026

   · 

  6 min read
• Press Releases

  United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

  June 1, 2026

   · 

  3 min read
• Press Releases

  BriaCell Therapeutics Announces Pricing of Offering

  June 1, 2026

   · 

  3 min read
• Press Releases

  Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

  June 1, 2026

   · 

  15 min read
• Press Releases

  Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

  June 1, 2026

   · 

  19 min read